Acromegaly improved with sandostatin LAR treatment / 대한내과학회지
Korean Journal of Medicine
;
: 643-646, 2007.
Article
in Korean
| WPRIM
| ID: wpr-112186
ABSTRACT
Cardiovascular disease is the most frequent cause of death in patients with acromegaly. Recently, long-term treatment with a somatostatin analogue (Sandostatin LAR) has been shown to be effective in controlling growth hormone (GH) and insulin like growth factor-1 (IGF-1) hypersecretion in most patients with acromegaly. Along with the effectiveness in the hormone profile, Sandostatin LAR has been reported to be effective for tumor mass shrinkage and clinical symptom improvement. We have encountered a female acromeglic patient with severe dilated cardiomyopathy and the patient was treated with Sandostatin LAR After treatment for 12 months, as seen by follow up echocardiography, the overall cardiac function was significantly improved. We report the case with a review of the literature.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Acromegaly
/
Somatostatin
/
Growth Hormone
/
Echocardiography
/
Cardiomyopathy, Dilated
/
Cardiovascular Diseases
/
Octreotide
/
Follow-Up Studies
/
Cause of Death
/
Insulin
Type of study:
Observational study
/
Prognostic study
Limits:
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS